newsfilter
← Latest News
GlobeNewswire·

60 Degrees Pharmaceuticals Announces Early Enrollment of First Seasonal Patient in Clinical Trial of Tafenoquine for Patients Hospitalized with Babesiosis

Enrollment is tracking ahead of schedule, allowing potential acceleration of key trial milestonesMinimum enrollment to support interim analysis expected as soon as early July 2026Randomized, double-blind,